GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,800 ($21.94) price target by stock analysts at Goldman Sachs Group Inc. in a research report issued on Wednesday. The firm presently has a a “buy” rating on the stock. Goldman Sachs Group Inc.’s price objective would indicate a potential upside of 7.98% from the company’s current price.

GSK has been the topic of a number of other research reports. Credit Suisse Group AG restated a “neutral” rating and set a GBX 1,800 ($21.94) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 14th. S&P Global Inc. set a GBX 1,650 ($20.11) target price on GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Wednesday, July 27th. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Tuesday, June 21st. BNP Paribas reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 29th. Finally, Citigroup Inc. set a GBX 1,800 ($21.94) target price on GlaxoSmithKline plc and gave the company a “buy” rating in a research report on Thursday, September 29th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of GBX 1,680.71 ($20.48).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc (LON:GSK) traded down 0.12% during midday trading on Wednesday, hitting GBX 1665.00. 5,782,299 shares of the stock traded hands. The firm’s market cap is GBX 80.94 billion. The company’s 50 day moving average price is GBX 1,651.49 and its 200 day moving average price is GBX 1,567.94. GlaxoSmithKline plc has a 12 month low of GBX 1,277.25 and a 12 month high of GBX 1,745.56.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

The company also recently announced a dividend, which was paid on Thursday, October 13th. Investors of record on Thursday, August 11th were issued a dividend of GBX 19 ($0.23) per share. This represents a yield of 1.12%. The ex-dividend date of this dividend was Thursday, August 11th.

In other news, insider Slaoui,Moncef bought 28 shares of the stock in a transaction that occurred on Friday, August 12th. The stock was bought at an average cost of GBX 2,208 ($26.91) per share, for a total transaction of £618.24 ($753.49). Also, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($20.63), for a total value of £169,300 ($206,337.60).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with's FREE daily email newsletter.